TomoTherapy, developer of a versatile radiation system used for the treatment of a variety of cancers, priced its IPO Tuesday evening. The company sold 11.7 million shares, 7% more than the 10.9 million originally planned, at a price of $19.00, representing a 19% premium on the midpoint of the $15.00-$17.00 range previously announced. Merrill Lynch and Piper Jaffray were the bookrunners on the deal. The stock is expected to begin trading on the NASDAQ under the ticker "TTPY" on Wednesday.
